In vitro activity of hypnophilin from Lentinus strigosus: A potential prototype for chagas disease and leishmaniasis chemotherapy

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 11, 2010, Pages 1054-1061

  Souza Fagundes, E M ^a,b   Cota, B B ^b   Rosa, L H ^c   Romanha, A J ^b   Correa Oliveira R ^b   Rosa, C A ^a   Zani, C L ^b   Teixeira Carvalho, A ^b   Martins Filho, O A ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Chagas disease; Chemotherapy; Hypnophilin; Immunomodulation; Leishmaniasis; Lentinus strigosus

Indexed keywords

HYPNOPHILIN; PANEPOXYDONE; PHYTOHEMAGGLUTININ; PLANT EXTRACT; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; CELL PROLIFERATION; CHAGAS DISEASE; CYTOTOXICITY; DOWN REGULATION; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEISHMANIA; LEISHMANIASIS; LENTINUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE;

LEISHMANIA AMAZONENSIS; LENTINUS STRIGOSUS; TRYPANOSOMA CRUZI; TRYPANOSOMATIDAE;

EID: 78649472557     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500108     Document Type: Article

References (24)

1. Kesselheim AS. Drug development for neglected diseases - the trouble with FDA review vouchers. N Engl J Med 2008; 359: 1981-1983.
2. Vermeersch M, Foubert K, da Luz RI, Van Puyvelde L, Pieters L, Cos P, et al. Selective anti-Leishmania activity of 13,28-epoxy-oleanane and related triterpene saponins from the plant families Myrsinaceae, Primulaceae, Aceraceae and Icacinaceae. Phytother Res 2009; 23: 1404-1410.
3. Boiani L, Aguirre G, Gonzalez M, Cerecetto H, Chidichimo A, Cazzulo JJ, et al. Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies. Bioorg Med Chem 2008; 16: 7900-7907.
4. Coura JR. Present situation and new strategies for Chagas disease chemotherapy - a proposal. Mem Inst Oswaldo Cruz 2009; 104 (Suppl 4): 549-554.
5. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop São Paulo 2002; 44: 29-37.
6. Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97: 3-24.
7. Cançado JR. Tratamento específico. In: Cançado JR, Chuster M (Editors), Cardiopatia chagásica. Rio de Janeiro: Fundação Carlos Chagas; 1985.
8. Krauth-Siegel RL, Inhoff O. Parasite-specific trypanothione reductase as a drug target molecule. Parasitol Res 2003; 90 (Suppl 2): S77-S85.
9. Krauth-Siegel RL, Shöneck R. Trypanothione reductase and lipoamide dehydrogenase as targets for a structure-based drug design. FASEBJ 1995; 9: 1138-1146.
10. Souza-Fagundes EM, Gazzinelli G, Parreira GG, Martins-Filho OA, Amarante-Mendes GP, Correa-Oliveira R, et al. In vitro activity of labdane diterpene from Alomia myriadenia (Asteraceae): immunosuppression via induction of apoptosis in monocytes. Int Immunopharmacol 2003; 3: 383-392.
11. Pegler DN. The genus Lentinus: a world monograph. London: Her Majesty's Stationery Office, Kew Bulletin Additional Series 10; 1983.
12. Cota BB, Rosa LH, Fagundes EM, Martins-Filho OA, Correa-Oliveira R, Romanha AJ, et al. A potent trypanocidal component from the fungus Lentinus strigosus inhibits trypanothione reductase and modulates PBMC proliferation. Mem Inst Oswaldo Cruz 2008; 103: 263-270.
13. Hamilton CJ, Saravanamuthu A, Eggleston IM, Fairlamb AH. Ellman's-reagent-mediated regeneration of trypanothione in situ: substrate-economical microplate and time-dependent inhibition assays for trypanothione reductase. Biochem J 2003; 369: 529-537.
14. Borges A, Cunningham ML, Tovar J, Fairlamb AH. Sitedirected mutagenesis of the redox-active cysteines of Trypanosoma cruzi trypanothione reductase. Eur J Biochem 1995; 228: 745-752.
15. Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC. Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 1996; 40: 2592-2597.
16. Jiang J, Xu Q. Immunomodulatory activity of the aqueous extract from rhizome of Smilax glabra in the later phase of adjuvant-induced arthritis in rats. J Ethnopharmacol 2003; 85: 53-59.
17. Gazzinelli G, Katz N, Rocha RS, Colley DG. Immune responses during human schistosomiasis mansoni. X. Production and standardization of an antigen-induced mitogenic activity by peripheral blood mononuclear cells from treated, but not active cases of schistosomiasis. J Immunol 1983; 130: 2891-2895.
18. Sathler-Avelar R, Vitelli-Avelar DM, Massara RL, Borges JD, Lana M, Teixeira-Carvalho A, et al. Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol 2006; 64: 554-563.
19. Tanowitz HB, Kirchhoff LV, Simon D, Morris SA, Weiss LM, Wittner M. Chagas' disease. Clin Microbiol Rev 1992; 5: 400-419.
20. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 2001; 1: 92-100.
21. Muelas-Serrano S, Le-Senne A, Fernandez-Portillo C, Nogal JJ, Ochoa C, Gomez-Barrio A. In vitro and in vivo anti-Trypanosoma cruzi activity of a novel nitro-derivative. Mem Inst Oswaldo Cruz 2002; 97: 553-557.
22. Den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. Developments in the treatment of visceral leishmaniasis. Exp Op Emerg Drugs 2009; 14: 395-410.
23. Umezawa K, Ariga A, Matsumoto N. Naturally occurring and synthetic inhibitors of NF-kappaB functions. Anticancer Drug Des 2000; 15: 239-244.
24. Erkel G, Wisser G, Anke T. Influence of the fungal NFkappaB inhibitor panepoxydone on inflammatory gene expression in MonoMac6 cells. Int Immunopharmacol 2007; 7: 612-624.